Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

The Lancet Oncology

Volumn 9, Issue 1, 2008, Pages 45-53

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEMALE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, ALKYLATING; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TIME FACTORS; TRIAZOLES;

EID: 37449028688     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70385-6     Document Type: Article

References (26)

1. Parkin D., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Anderson W., Chatterjee N., Ershler W., and Brawley O. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76 (2002) 27-36
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
5. Braithwaite R., Chlebowski R., Lau J., George S., Hess R., and Col N. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937-947
6. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. Am Heart J 153 (2007) 182-188
7. Wysowski D., Honig S., and Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 346 (2002) 1832-1833
8. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
9. Coates A., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
10. Coombes R., Kilburn L., Snowdon C., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
11. Winer E., Hudis C., Burstein H., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
12. Goldhirsch A., Wood W., Gelber R., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
13. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
15. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
16. Cox D. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
17. Jones M., and Wand M. Kernel smoothing (1994), CRC Press, Boca Raton, FL
18. Food and Drug Administration (COSTART). The coding symbols for thesaurus of adverse reaction terms, 5th edn, 1995.
19. Viale G., Regan M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25 (2007) 3846-3852
20. Dowsett M., Allred D., and on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100 suppl 1 (2006) S21 (abstr 48).
21. Hanrahan E., Gonzalez-Angulo A., Giordano S., et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25 (2007) 4952-4960
22. Coleman R., and on behalf of the ATAC Trialists' Group. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. Proc Am Soc Clin Oncol 24 suppl 18 (2006) (abstr 511).
23. Eastell R, Adams JE, Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results from the ATAC trial (18233230). J Clin Oncol (in press).
24. Eastell R., Van Poznack C., Hannon R., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. J Bone Miner Res 22 suppl 1 (2007) S113
25. Singh S., Cuzick J., Edward R., et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). Breast Cancer Res Treat 106 suppl 1 (2007) S9 abstr 28.
26. Fisher B., Costantino J., Redmond C., Fisher E., Wickerham D., and Cronin W. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86 (1994) 527-537